Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Sales
View:
Post by hoffbag on Oct 27, 2021 11:59am

Sales

At the end of the day sales will determine whether Ceapro succeeds or fails.  I stay focused on that.  All of this effort has to translate into increased sales or you are wasting time.  Ceapro and the non-Prophet have been very good at the game of distraction, but as is apparent by current valuations, investors arent buying it.

In the OBG instance, impact of OBG on cholesterol is well publicized, nothing groundbreaking here.  I am pretty sure Ceapro could already have marketed a pill for "borderline" cholesterol readings where the MD / patient dont want to prescribe / take statins. At the end of the day they will have to have the ability to market a product and compete against other brands anyways so why study?  Competitors will use that study data to market their products.  Differentiation has to  come from the process and purity of compound, always market concerns.

Plans to build mean nothing.  So if you announce you are planning to build a plant.....begs the question why?  Follow up with the statement that we have increased volume commitments for x and need to increase capacity. That gets shareholders excited.

ACTION = SALES
Interesting data on YBG but the market yawns.  Why....because no action, just data.  Avenanthramide market commercially exclusive to Ceapro....who cares, no action.  Co-enzyme Q10-Beta glucan ready to go.....nothing. 

So far Ceapro has shown that they are good at wasting time.and have no desire to roll up their sleeves and take it to the market.  They dont seem to recognize an issue or take action to counter measure it.  Ceapro stock languishes because of this culture.  This has nothing to do with a quick buck investor mindset, everything to do about Ceapro.  

To add a humorous analogy.... Give these guys a truck of ice cold bottled water in the middle of the Sahara desert and they would conduct taste testing trials ..... rather than sell it.
Comment by ZoranSto on Oct 27, 2021 12:26pm
Interesting analogy....I would add that ceapro needs to show that the water will quench your thirst, there are no contaminents, and the testing to prove it. Otherwise it could be a truck of bottled water from Flint Michigan....
Comment by Ciao on Oct 27, 2021 12:36pm
The plan is and has been for the BG pill to have health claims backed up by a clinical study for their specific pharma grade product. That will differentiate themselves from the run of the mill products you see on the shelves. Depending on the results, it will be a nutraceutical or a regulated product and that will drive sales. Let's be patient to see the results and what strategy will be ...more  
Comment by prophetoffacts on Oct 27, 2021 1:12pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities